AI Case Study

Abbvie achieves 90% cumulative medication adherence among patients with schizophrenia using image recognition

Abbvie used AiCure’s artificial intelligence platform to visually confirm medication ingestion. This has facilitated continuous monitoring of patient treatment leading to better compliance and streamlining of clinical trials by reducing sample size.

Industry

Healthcare

Pharmaceuticals And Biotech

Project Overview

AiCure uses visual recognition to confirm medication ingestion using smartphones, and has managed to significantly increase medication adherence among patients. This was tested in patients with Schizophrenia, measured by drug concentration levels.

Reported Results

90% medication adherence compared to 72% before.

Technology

Function

Customer Service

Technical And Product Support

Background

Abbvie is a biopharmaceutical company founded in 2013.

Benefits

Data